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Abstract
Background Clinical trials report severe hypoglycaemic
events as the number of patients with at least one event out
of the total randomised or number of events for a given
total exposure. Different network meta-analysis models
have been used to analyse these different data types.
Objective This aim of this article was to establish the
impact of using the different models on effectiveness, costs
and health utility estimates.
Methods We analysed a dataset used in a recent network
meta-analysis of severe hypoglycaemic events conducted
to inform National Institute for Health and Care Excellence
recommendations regarding basal insulin choice for
patients with type 1 diabetes mellitus. We fitted a model
with a binomial likelihood reporting odds ratios (using a
logit link) or hazard ratios (complementary log-log link), a
model with a Poisson likelihood reporting hazard ratios and
a shared-parameter model combining different types of
data. We compared the results in terms of relative effects
and resulting cost and disutility estimates.
Results Relative treatment effects are similar regardless of
which model or scale is used. Differences were seen in the
probability of having an event on the baseline treatment
with the logit model giving a baseline probability of 0.07,
the complementary log-log 0.17 and the Poisson 0.29.
These translate into differences of up to £110 in the yearly
cost of a hypoglycaemic event and 0.004 in disutility.
Conclusion While choice of network meta-analysis model
does not have a meaningful impact on relative effects for
this outcome, care should be taken to ensure that the
baseline probabilities used in an economic model are
accurate to avoid misrepresenting costs and effects.
Key Points
The method used to model severe hypoglycaemic
events can have an impact on the estimated
probability of having an event. This article shows
that some statistical modelling methods give a lower
probability while others give higher.
As probabilities are the inputs used in economic
models, a lower or higher probability can have a
substantial impact on the costs and utilities
estimated.
It is important to ensure that probabilities of severe
hypoglycaemic events are accurately calculated to
avoid misrepresenting the cost effectiveness of
treatments.
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1 Background
Severe hypoglycaemia can occur in people with diabetes
mellitus who take insulin and other anti-diabetic treat-
ments. Clinical trials use variable definitions for severe
hypoglycaemia but it is generally defined as having low
blood glucose levels that require assistance from another
person to treat and is classed as a diabetic emergency that
can lead to seizures, coma or death [1]. Trials also report
hypoglycaemic events in different forms. Some report the
number of patients who experienced at least one event out
of the total number randomised (risk) and others report the
number of events for a given total exposure (rate). This
makes combining results from different trials to conduct a
meta-analysis based on aggregate data alone a challenging
task and poses a question about whether there are advan-
tages of using one outcome over another.
In the context of economic modelling, the costs and
quality of life (QoL) losses associated with these events
should be taken into account. Hence, measuring the risk of
having a hypoglycaemic event as opposed to the rate/
number of events, could lead to underestimating the costs
and QoL losses associated with these events as only the
costs and disutilties associated with one event will be
considered. Results of economic analyses, in terms of the
most cost-effective treatment, often hinge on small differ-
ences in costs and utilities and it is therefore important to
represent these accurately. The issues highlighted in this
article are therefore relevant not only in the case of severe
hypoglycaemic events but in any situation where repeated
events in the same patient are possible.
Published Bayesian network meta-analyses (NMAs) of
trials of treatments to prevent hypoglycaemic events have
used either the binomial with logit link [2] for data reported
as the risk of an event, or Poisson with log link [3] for data
reported as the rate of events. These models estimate rel-
ative treatment effects as odds ratios or hazard ratios,
respectively. Another model that would be considered
suitable for such data is the binomial model with a com-
plementary log-log (clog-log) link [4]. This model assumes
an underlying Poisson rate of events, but can be used when
data are reported as the risk of an event after a certain time
period. In the first part of this article, we use the data from
the systematic review and NMA conducted to inform rec-
ommendations regarding basal insulin choice for patients
with type 1 diabetes from the 2015 National Institute for
Health and Care Excellence (NICE) guideline [5] to com-
pare the relative effectiveness results from the three sug-
gested models. These results will then be compared with
those from a shared-parameter model [4], which has the
advantage of being able to combine both risk and rate data.
The second part of this article considers the impact of
using the binomial with logit or clog-log links and Poisson
models on conducting a meta-analysis of studies to inform
baseline effects. The baseline probability of an event is a
person’s risk, or probability, of having an event when using
the reference treatment, often placebo. The baseline prob-
ability of an event can be informed by using values from a
cohort study or local database, using the reference treat-
ment arm from a particular trial, which represents the UK
population, or by performing a meta-analysis of relevant
treatment arms from all or a subset of included trials. In
this study, we conduct Bayesian meta-analyses of all the
reference treatment arms of the studies that compared the
reference treatment, glargine (once), to any of the
remaining insulin regimens [6].
Absolute probabilities of an event on each treatment are
the inputs most commonly used in economic models. As
these are calculated by applying the relative effects of each
treatment to the baseline effect, different assumptions
about this baseline effect can have a substantial impact on
the costs and QoL outputs of economic models, even when
relative effects are unchanged. We assess the impact dif-
ferent data types and modelling strategies could have on
costs and QoL estimates.
2 Methods
2.1 Relative Effects
An NMA uses all the available evidence, both direct and
indirect, to produce estimates of the relative effects of each
treatment compared with every other in a network, even if
some pairs of treatments have not been directly compared
[4, 7–10] Network meta-analyses were conducted to
simultaneously compare eight insulin regimens: insulin
detemir once daily, insulin detemir twice daily, degludec
once daily, insulin neutral protamine Hagedorn (NPH)
once daily, insulin NPH twice daily, insulin NPH four
times daily, insulin detemir once or twice daily and insulin
NPH once or twice daily to the reference treatment, insulin
glargine once daily. The network of evidence for each
model is shown in Fig. 1 and the data used in each model
are given in Appendix A of the Electronic Supplementary
Material (ESM).
All analyses were conducted within a Bayesian framework
using WinBUGS 1.4.3, Boca Raton, FL [11]. The binomial
and Poisson models were based on the approach and code
provided by theNICEDecisionSupportUnit [4]. The code for
the shared-parameter model was adapted from the code pro-
vided by the NICE Decision Support Unit [4]. The code used
in each model is provided in Appendix B of the ESM.
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Twenty studies were available for meta-analysis.
Twelve studies reported data as both the risk of having a
hypoglycaemic event and the rate of events, while four
studies only reported the risk and four only reported the
rate. All studies met the inclusion criteria for the NICE
guideline on type 1 diabetes [5] and were deemed eligible
to be compared in a NMA based on the similarity of the
populations included. In terms of baseline glycosylated
haemoglobin, the percentage was similar between most of
the studies (between 7.5 and 8.5%) and none were below
7%. The baseline age was also similar between studies
(most were between 35 and 45 years of age). Further
details on the inclusion and exclusion criteria are provided
in the NICE guideline [5].
The 16 studies that reported risk data were synthesised
using two alternative models. The first model adopts a
binomial likelihood with a logit link function, and gener-
ates output on a log-odds scale. Relative treatment effects
are reported as posterior median odds ratios and 95%
credible intervals (CrIs). This model assumes linearity of
effects on the logit scale and does not consider follow-up
time of the trials, assuming that differences in follow-up
time have no effect on how likely a patient is to have a first
severe hypoglycaemic event. This model will henceforth be
referred to as the logit model.
The follow-up time in the included trials varied from
4 weeks to 2 years. The second model, assumed a constant
rate of events, to estimate the probability of events
occurring over time. Again, a binomial likelihood is
assumed, but a clog-log link function is used, which results
in outputs on a log-hazard scale. Relative treatment effects
are reported as posterior median hazard ratios and 95%
CrIs. We will refer to this as the clog-log model.
For the 16 studies that reported rates over person-time,
a Poisson model with a log link function was used to
estimate the probability of events occurring over time.
This model also produces outputs on a log-hazard scale.
Relative treatment effects are reported as posterior med-
ian hazard ratios and 95% CrIs. This model, like the clog-
log model, assumes that in each arm of each trial the
hazard is constant over the follow-up period and also that
the events are independent; thus, a person who has
already had an event is no more likely to have a subse-
quent event than a person who has not yet had their first
event.
Fig. 1 Network plots of studies included in each analysis. The lines
connecting each pair of interventions represent a direct comparison in
one or more randomised controlled trials. The width of the lines is
proportional to the number of trials directly comparing each pair of
interventions. The size of each node is proportional to the number of
participants randomised to that treatment (sample size)
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An advantage of taking a Bayesian approach to esti-
mation is that it is straightforward to extend to shared-
parameter models where different trials report outcomes in
different formats but from a common underlying model. As
both rate and risk data can be synthesised on a log-hazard
scale, it is possible to combine both in a shared-parameter
model using a binomial likelihood with a clog-log link
function for the risk data and a Poisson likelihood with a
log link function for the rate data [4]. This assumes that,
regardless of how the data are reported, the incidence of
events has the characteristics of a homogeneous Poisson
process. This model also assumes that after a patient has
their first event, the rate of subsequent events does not
change. A model of this type was estimated to combine the
risk and rate data. This model could incorporate all 20
studies. For studies that reported both risk and rate data,
rate data were given preference. Relative treatment effects
are reported as posterior median hazard ratios and 95%
CrIs.
Both fixed- and random-effects models were estimated.
The goodness of fit of each model to the data was measured
using the posterior mean of the residual deviance, which is
a measure of the magnitude of the difference between the
observed data and the model predictions for those data.
Smaller values are preferred, and in a well-fitting model,
the posterior mean residual deviance should be close to the
number of data points [12]. The Deviance information
criterion (DIC), which is equal to the sum of the posterior
mean of the residual deviance and the effective number of
parameters and penalises model fit with model complexity,
was used as the basis for model comparison with lower
values being favoured [12]. Differences of less than 3 were
not considered meaningful and the simpler model was
selected. Model selection was also based on the posterior
median between-study heterogeneity and its CrI. Consis-
tency between the different sources of indirect and direct
evidence was explored statistically by comparing the fit of
a model assuming consistency with a model that allowed
for inconsistency (also known as an unrelated treatment-
effect model). In this type of model, each of the compar-
isons for which evidence is available represents a separate
unrelated basic parameter to be estimated [13]. If the
inconsistency model had the smallest posterior mean
residual deviance, heterogeneity or DIC value, then this
would indicate potential inconsistency in the data.
Results are reported in terms of relative effects of each
treatment compared with the reference treatment, glargine
(once), for each of the models analysed. The posterior
median of the ranking of each treatment (and 95% CrIs) is
also reported, with the convention that the lower the rank
the better the treatment.
2.2 Absolute Probabilities
We also report the absolute probability of an event on each
treatment, using the relative effects from each model. To
estimate this, we needed to make an assumption about the
absolute effect of the reference treatment, in this case,
glargine (once), and apply this to the relative effects.
Glargine (once) was chosen as the reference treatment as it
was in the centre of the network of evidence and was
directly compared to the most other treatments, increasing
the stability of its relative effect estimates.
We derived the probability of an event on glargine
(once) by conducting a Bayesian meta-analysis of all the
glargine (once) arms of the studies that compared glargine
(once) with any of the remaining insulin regimens. This
was also done within a Bayesian framework using Win-
BUGS 1.4.3 and based on the approach described in Dias
et al. [6]. The code is provided in Appendix B of the ESM.
There were eight studies reporting risk data that com-
pared glargine (once) with any of the remaining insulin
regimens (Appendix A of the ESM). A separate analysis of
these arms was first carried out on the log-odds scale to
apply to the relative effects from the logit model. The
baseline probability was also estimated using the clog-log
link (log-hazard ration scale) through a meta-analysis of
the glargine (once) arms of the risk data.
The baseline rate of severe/major hypoglycaemia,
defined here as the number of severe/major hypoglycaemic
events per person-year of follow-up when using insulin
glargine (once), was also calculated using a Poisson like-
lihood. There were seven studies in the rate data that
compared glargine (once) to any of the remaining insulin
regimens (Appendix A of the ESM).
Synthesising risk data using a binomial likelihood gives
the absolute probability of having a hypoglycaemic event
in 1 year, whereas synthesising rate data using a Poisson
likelihood gives an absolute rate of events in 1 year. To
make the results comparable, the absolute rates from the
Poisson model were transformed into probabilities using
the formula:
p ¼ 1 exp rtð Þ
where p is the probability, r is the rate and t is the time
period of interest (in this case, 1 year) [14]. This conver-
sion assumes constant rates.
Both fixed- and random-effects models were estimated
for each model and the goodness of fit of each model to the
data was again measured by comparing the posterior mean
of the summed residual deviance, the DIC and the posterior
mean between-study heterogeneity. The results from the
three models and their effect on the absolute probabilities
are explored below.
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2.3 Estimating Costs and Disutilities
To demonstrate the difference that the use of each of these
models could have on costs and disutilities, we used a cost
of £333 per severe hypoglycaemic event, estimated from
Hammer et al. [15], and a utility decrement of - 0.012 for
anyone experiencing a severe hypoglycaemic event (taken
from NICE clinical guideline NG17 on type 1 diabetes [5]),
and multiplied these by the absolute probabilities of having
an event calculated from the three models.
3 Results
3.1 Model Fit
For the logit and clog-log models, the fit of the fixed-ef-
fects model was comparable to the random-effects model
with the fixed-effects models having a higher residual
deviance but a lower DIC. However, for comparison with
the Poisson model (where random effects are required), we
assess consistency and present results using random effects
for all. No meaningful differences were observed in pos-
terior mean residual deviance or DIC values when com-
paring the random-effects consistency and inconsistency
models, suggesting that there was no evidence of incon-
sistency. The goodness-of-fit and model selection statistics
for the models are reported in Appendix C of the ESM.
3.2 Relative Effects
Reported results are based on the random-effects NMA
models, assuming consistency. Results in terms of relative
effects were relatively consistent across all models. Fig-
ure 2 shows the relative effects compared with glargine
(once) when using each model, with the logit model on the
log odds ratio scale and the other models on the log hazard
ratio scale. The figure shows that there is very little dif-
ference between treatments in the reduction of events and
that choice of model has little effect on this. One exception
is for detemir (once), which seems more likely to increase
hypoglycaemic events compared with glargine (once) in
the Poisson model but is likely to decrease events in all
other models. This suggests that there is a higher chance of
having repeated events on detemir (once), which is not
captured by the data included in the other models. How-
ever, overall for this dataset, choice of model scale has
little impact on results and no firm conclusions can be
drawn on which is the best treatment based on efficacy
alone, owing to the uncertainty in the results.
Table 1 lists the treatments in terms of median rank and
95% CrIs. In the logit and clog-log models, detemir (once)
has the highest median rank (second, CrI first to sixth)
followed by detemir (once/twice) [third, CrI first to sixth].
Detemir (once) is replaced by detemir (once/twice) as the
highest-ranking treatment in the Poisson and shared-pa-
rameter models. Neutral protamine Hagedorn (once/twice)
is the lowest ranked treatment in all models. However, the
wide CrIs around these ranks reflect the considerable
uncertainty in the relative treatment effects and no firm
conclusions on which is the best treatment can be drawn
(Fig. 2).
3.3 Absolute Probabilities
The probability of having a hypoglycaemic event on the
reference treatment was calculated separately using a logit,
clog-log and Poisson model [6]. In each case, the random-
effects model was a better fit to the data.
The single-arm meta-analysis of the eight studies com-
paring glargine (once) and reporting risk data using a logit
model, produced a mean baseline probability of sev-
ere/major hypoglycaemic events of 0.07 (95% CrI
0.04–0.13) when using glargine (once). The meta-analysis
using the same studies but with a clog-log model produced
a mean baseline probability of severe/major hypogly-
caemic events at 1 year of 0.17 (95% CrI 0.06–0.34). The
analysis of the seven studies comparing glargine (once) and
reporting rate data, using a Poisson likelihood, produced a
mean baseline rate of severe/major hypoglycaemic events
of 0.38 events per person-year (95% CrI 0.07–1.21). When
this was transformed into a probability at 1 year, the
baseline probability of having an event when using glar-
gine (once) was 0.29 (95% CrI 0.07–0.7).
The difference in the baseline probabilities estimated is
the result of the different time periods assumed. The logit
model assumes the probability is the same for any time
period but reflects the probability of an event over the study
follow-ups in the contributing data. These have an average
follow-up time of 5 months. The clog-log model gives a
probability of an event over a 1-year period; thus, it follows
that this will be larger. The Poisson model reflects the
possibility of multiple events, which again leads to a higher
probability. The Poisson model also has slightly different
data included, owing to not all studies reporting both risk
and rate data, although five out of the seven studies are
common across all three models (Appendix A of the ESM).
Table 2 shows the absolute probabilities of events when
the probabilities of having an event on glargine (once) from
each of the baseline meta-analysis models are applied to
the relative effects from the corresponding NMA model.
This table shows that despite the relative effects being very
similar (Fig. 2), the difference in baseline probabilities
causes the absolute probabilities to differ considerably
across models.
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3.4 Expected Costs and Disutilities
Table 3 shows the expected costs from each of the models
and Table 4 shows the expected disutilities. Although the
ranking of costs and disutilities from lowest to highest is
similar across the models, there is considerable difference in
the estimated values. The expected cost of detemir (once),
for example, varies from £13.29 per year when the absolute
probabilities from the logit model are used, to £123.28 when
the values from the Poissonmodel are used. The difference in
disutilties is less apparent as the figures are small but the
change in magnitude across the models is the same.
Fig. 2 Mean differences in hypoglycaemic events. Negative values
mean that the treatment reduces hypoglycaemic events compared with
Glargine (once). Treatment legend: 2. Neutral protamine Hagedorn
[NPH] (twice); 3. Detemir (once); 4. Detemir (twice); 5. Degludec
(once); 6. NPH (once); 7. NPH (once/twice); 8. Detemir (once/twice).
Clog-log complementary log-log
Table 1 Posterior median rank
and 95% credible intervals
(CrIs)
Treatment Logit and clog-log Poisson Shared parameter
Median rank 95% CrIs Median rank 95% CrIs Median rank 95% CrIs
Detemir (once) 2 (1–6) 5 (1–8) 3 (1–8)
Detemir (once/twice) 3 (1–6) 2 (1–6) 2 (1–6)
Detemir (twice) 4 (1–8) 4 (1–8) 4 (1–8)
NPH (once) 4 (1–8) 5 (1–8) 4 (1–8)
Glargine (once) 5 (2–7) 4 (2–7) 5 (2–7)
NPH (twice) 5 (1–8) 5 (1–8) 5 (1–8)
Degludec (once) 6 (2–8) 4 (1–8) 5 (1–8)
NPH (once/twice) 6 (3–8) 6 (2–8) 7 (3–8)
clog-log complementary log-log, NPH Neutral protamine Hagedorn
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4 Discussion
This article found that, in the context of treatments to
reduce hypoglycaemic events, choice of scale for the rel-
ative treatment effects does not have a significant impact
on efficacy results. Although the Poisson model is expected
to be the most appropriate for modelling these data as it
takes into account different follow-up times and repeated
events, because severe hypoglycaemic events are rare and
occur at a constant rate, modelling relative treatment
effects using odds ratios rather than hazard ratios still
captures the differences between treatments.
However, as trials currently report severe hypogly-
caemic events in different forms, and may continue to do
Table 2 Absolute probabilities of having a hypoglycaemic event (at 1 year)
Treatment Absolute probability (logit) Absolute probability (clog-log) Absolute probability (Poisson)
Mean 95% CrIs Mean 95% CrIs Mean 95% CrIs
Detemir (once) 0.04 (0.01–0.11) 0.10 (0.02–0.29) 0.37 (0.04–0.97)
Detemir (once/twice) 0.04 (0.01–0.1) 0.11 (0.03–0.29) 0.2 (0.03–0.61)
NPH (once) 0.06 (0.01–0.17) 0.15 (0.03–0.43) 0.33 (0.05–0.86)
Glargine (once) 0.07 (0.04–0.12) 0.17 (0.07–0.34) 0.29 (0.07–0.7)
NPH (once/twice) 0.08 (0.04–0.16) 0.20 (0.07–0.43) 0.4 (0.08–0.91)
Degludec (once) 0.09 (0.03–0.18) 0.21 (0.07–0.47) 0.31 (0.05–0.81)
Detemir (twice) 0.12 (0–0.71) 0.26 (0–1) 0.38 (0–1)
NPH (twice) 0.14 (0–0.75) 0.29 (0–1) 0.39 (0–1)
clog-log complementary log-log, CrIs credible intervals, NPH Neutral protamine Hagedorn
Table 3 Expected costs (£) Treatment Expected cost (logit) Expected cost (clog-log) Expected cost (Poisson)
Mean 95% CrIs Mean 95% CrIs Mean 95% CrIs
Detemir (once) 13.29 (2.97–36.83) 34.21 (6.88–97.52) 123.8 (13.21–323)
Detemir (once/twice) 14.41 (4.17–34.16) 38.16 (9.81–97.26) 66.91 (10.31–201.7)
NPH (once) 20.42 (4.38–57.71) 51.11 (10.14–145) 110.4 (18.24–287.6)
Glargine (once) 22.65 (11.76–39.04) 56.14 (22.35–112.6) 95.59 (22.34–233.5)
NPH (once/twice) 28.08 (12.17–53.85) 68.36 (24.27–144.5) 134.6 (27.28–302.8)
Degludec (once) 29.63 (11.53–61.19) 71.1 (23.44–156.8) 102.7 (18.24–287.6)
Detemir (twice) 41.67 (0.35–237.9) 87.82 (1.13–332.8) 126.7 (1.43–333)
NPH (twice) 47.37 (0.44–251.1) 97.82 (1.43–333) 128.3 (1.55–333)
clog-log complementary log-log, CrIs credible intervals, NPH Neutral protamine Hagedorn
Table 4 Expected disutilities
Treatment Expected disutility (logit) Expected disutility (clog-log) Expected disutility (Poisson)
Mean 95% CrIs Mean 95% CrIs Mean 95% CrIs
Detemir (once) 0.000 (- 0.001 to 0) - 0.001 (- 0.004 to 0) - 0.004 (- 0.012 to 0)
Glargine (once) - 0.001 (- 0.001 to 0) - 0.002 (- 0.004 to - 0.001) - 0.003 (- 0.008 to - 0.001)
Detemir (twice) - 0.001 (- 0.009 to 0) - 0.003 (- 0.012 to 0) - 0.005 (- 0.012 to 0)
Degludec (once) - 0.001 (- 0.002 to 0) - 0.003 (- 0.006 to - 0.001) - 0.004 (- 0.01 to - 0.001)
NPH (once) - 0.001 (- 0.002 to 0) - 0.002 (- 0.005 to 0) - 0.004 (- 0.01 to - 0.001)
NPH (once/twice) - 0.001 (- 0.002 to 0) - 0.002 (- 0.005 to - 0.001) - 0.005 (- 0.011 to - 0.001)
Detemir (once/twice) - 0.001 (- 0.001 to 0) - 0.001 (- 0.004 to 0) - 0.002 (- 0.007 to 0)
NPH (twice) - 0.002 (- 0.009 to 0) - 0.004 (- 0.012 to 0) - 0.005 (- 0.012 to 0)
clog-log complementary log-log, CrIs credible intervals, NPH Neutral protamine Hagedorn
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so, the use of a shared-parameter model is recommended as
this allows the incorporation of both risk and rate data;
making use of all available data. Although incorporating
both types of data did not make a considerable difference to
results in this example, this may change in a different
example.
Where extra care should be taken is in ensuring that the
baseline probability of an event used in an economic model
is realistic and accurate to avoid over or underestimation of
the costs and effects. This article has demonstrated that
choice of model and scale can have a significant effect on
this baseline probability, with differences of between 0.07
and 0.29 found depending on the model and data used. It
has also shown that when this baseline probability is
applied to the relative effects from the corresponding
model, significant differences can be seen in cost and
utility estimates. It is feasible that these differences could
lead to changes in the decision as to which treatment is
most cost effective when the absolute probabilities are used
in cost-effectiveness models.
The different assumptions made by the models and the
data used explain the differences in results. The Poisson
and clog-log model allow for a constant rate of events over
time. These models are preferable to the logit model, which
estimates a probability of at least one event that is
unchanged over time. In addition, the Poisson data allow
for more than one event per person, which allows a better
estimation of the rate of events, when multiple events can
occur (as is the case here).
The sensitivity of cost-effectiveness results to the
hypoglycaemic event rate has been highlighted in several
studies. Gschwend et al. [16], who used the IMS CORE
Diabetes Model to estimate the cost effectiveness of insulin
detemir compared with NPH insulin in patients with type 1
diabetes using data from a 2-year randomised controlled
trial, showed that results were highly sensitive to the event
rate used with small differences in the rate causing detemir
to lose dominancy over NPH.
McEwan et al. [17] describe the Cardiff Type 1 Diabetes
Model and report the quality-adjusted life-year impact of
changes in the rate of hypoglycaemic events. The default
baseline rate of a severe hypoglycaemic event used in the
model is based on the probability of self-reporting a severe
hypoglycaemic event of 0.46 in patients with type 1 dia-
betes from an observational study carried out by the UK
Hypoglycaemia Study Group [18]. Modifying hypogly-
caemia frequency by - 10, - 20 or -30% resulted in
changes to discounted quality-adjusted life-years of ? 0.05,
? 0.11 and ? 0.17, respectively, and modifying hypogly-
caemia frequency by ? 10, ? 20 or ?30% resulted in
changes to discounted quality-adjusted life-years of - 0.05,
- 0.09 and - 0.13. This emphasises the importance of
accurately reflecting the probability of hypoglycaemic
events in economic models.
The difficulty of calculating the cost of hypoglycaemic
events based on studies reporting events in different forms
has also been highlighted by Jonsson et al. [19] who used a
cost-of-illness approach, based on an incidence methodol-
ogy, to estimate the cost of hypoglycaemia in patients with
type 2 diabetes. The incidence of hypoglycaemia was based
on findings from several published studies, some reporting
the number of events per person-years and some reporting
the percentage of patients experiencing an event. They
stated that the risk of hypoglycaemic events may therefore
be slightly underestimated but did not adjust for this. Our
analysis shows that this underestimation could potentially
have a significant impact on cost-effectiveness results.
A strength of this work is that the dataset used to
compare the different models in this paper is the same as
that used in the NICE guideline on type 1 diabetes. The
systematic review carried out to inform this guideline
found 20 studies comparing basal insulin regimens but
reporting different outcome measures. For the guideline, it
was decided to only use the 16 studies that reported rate
data and analyse these using a Poisson model. This article
has demonstrated the difference in results had they opted to
use the risk data, as has been done in a previous NMA [2].
The limitation of using these 20 studies reporting dif-
ferent outcome measures is that slightly different number
of trials, and hence data, have gone into each analysis. The
results are therefore not completely comparable and this
may be a source of heterogeneity. It is evident from the
network plots in Fig. 1 which direct comparisons are
included in the logit/clog-log and Poisson models and
which are missing. An alternative method would be to only
include the 12 studies reporting both risk and rate data in
each analysis and compare results on this basis, although
this would mean excluding data, which will reduce the
power of the analysis, making the networks even more
uncertain. The strength of the shared-parameter model
proposed here is that it can incorporate all the data and we
recommend using this model wherever possible. There is,
however, a relatively small number of studies per com-
parison, even in the shared-parameter model, leading to
sparse networks. This means that the analyses have low
statistical power to detect differences between the included
treatments and it is not possible to make a recommendation
regarding the optimal basal insulin regimen based solely on
these analyses.
Another issue to consider is the uncertainty in the lit-
erature as to the exact definition of severe hypoglycaemic
events, which may lead to between-trial heterogeneity in
analyses such as these. The NICE guideline defined severe
hypoglycaemia as ‘a blood glucose level that is sufficiently
low to cause a reduced level of function in an individual
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such that they are unable to self-manage a hypoglycaemia
episode and require help from another individual to achieve
normoglycaemia.’ Most of the studies included in these
analyses were in line with this definition, referring to the
person needing assistance from another to treat, although
some went into more detail, specifying the exact blood
glucose level cut-off. Standardisation in this regard is
recommended to reduce uncertainty in future analyses.
A further limitation is the lack of access to patient-level
data. Insulin regimens that reduce complications such as
severe hypoglycaemia are likely to also improve the sta-
bility of glycosylated haemoglobin, a reflection of average
plasma glucose levels over the medium term (2–3 months),
and also to reduce the occurrence of long-term complica-
tions and premature mortality [20–22] All of these are
important factors when choosing the most appropriate
treatment, but it is not possible to disentangle these effects
with aggregate data.
In terms of future research, a further model comparison
that could be made is with the negative binomial model,
which is useful in the case of overdispersed data, i.e. when
the observed variance is greater than expected under a
Poisson model. The negative binomial is more flexible than
the Poisson distribution, although it includes the Poisson
distribution as a limiting case. We have not yet seen this
model implemented in a meta-analysis context and because
we only have aggregate data on the number of events per
person-year, we did not have reason to suspect over-dis-
persion; thus, we chose to use the simpler Poisson model,
which fitted well. Because of the flexibility of WinBUGS,
the model could be adapted to include this more flexible
approach, if required [11].
In addition, we were unable to access the IMS Core
Diabetes Model [23] (which was used to assess cost
effectiveness in the NICE guideline) and re-estimate the
cost effectiveness using the different probabilities obtained.
This is also an area for future research, as it would deter-
mine whether the differences in probabilities of severe
hypoglycaemic events identified would in fact impact on
the treatment decision.
In general, we recommend using the model that best fits
with the underlying data-generating process. In the case of
severe hypoglycaemic events, the Poisson model for the
rate of events per person-year is the most appropriate.
Based on the results from this model and the cost and
disutilites of an event alone, detemir (once/twice) is the
best intervention. The findings of this study suggest that in
the case of severe hypoglycaemic events, when repeated
events are taken into account, the baseline probability of
having an event on glargine (once) is 0.29 but with wide
CrIs of 0.07–0.7. Further exploration should be given to
this baseline probability to ensure that it is accurate for use
in economic models.
5 Conclusion
This work has shown that choice of model and scale has
little impact on relative effectiveness or on the ranking of
basal insulin regimens from best to worst. No firm con-
clusions can be drawn with regard to the best basal insulin
regimen for preventing severe hypoglycaemic events owing
to the sparsity of the data and uncertainty in the networks.
However, we have shown that, despite this uncertainty in
terms of relative effects, it is possible for incorrect conclu-
sions to be drawn in terms of costs and disutilites, as absolute
probabilities of events can easily be underestimated if the
baseline probability does not take repeated events into
account. This is particularly important in health economic
models where small differences can have a considerable
impact on results. Care should therefore be taken to choose
an appropriate outcome measure when synthesising data on
repeated events for use in an economic model.
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